Kolexia
Guiu Severine Oncologie médicale
Guiu Severine
Oncologie médicale
Icm Montpellier
Montpellier, France
136 Activités
62 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du sein triple-négatives Métastase tumorale Carcinomes Cellules tumorales circulantes Carcinome canalaire du sein Récidive tumorale locale Tumeurs du cerveau Carcinome lobulaire

Collaborateurs

Voir plus
Jacot William
Jacot William
Icm Montpellier, Montpellier, France
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Desmoulins Isabelle
Desmoulins Isabelle
Centre Georges-François Leclerc, Dijon, France

Industries

Voir plus
Lilly
16 collaboration(s)
Dernière en 2023
Pfizer
15 collaboration(s)
Dernière en 2023
Novartis
6 collaboration(s)
Dernière en 2022
Daiichi Sankyo
5 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
DOLAF: An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib
Essai Clinique (Unicancer)   02 février 2024
ALCINA: Analysis of Circulating Tumor Markers in the Blood
Essai Clinique (Institut Curie)   01 février 2024
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Journal for immunotherapy of cancer   30 janvier 2024
First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.
Cancer medicine   22 décembre 2023
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer.
British journal of pharmacology   29 novembre 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA oncology   19 octobre 2023
483P Prognostic value of androgen receptor expression in patients with advanced triple-negative metastatic breast cancer treated with sacituzumab govitecan: A French multicentre retrospective study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancer
Abstract Book of ESMO Breast Cancer 2023, Berlin, Germany, 11-13 May 2023   01 mai 2023
CANTO: A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Cancer - Breast and Lung.
Essai Clinique (Unicancer)   20 avril 2023
CHACRY-1501: Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Essai Clinique (Centre Oscar-Lambret)   13 février 2023